DNA Nanobots Raises $3.5 Million to Advance Programmable, Non-Viral Gene Therapy Platform
DNA Nanobots, a biotechnology company pioneering self-assembling nanoscale therapeutics, has secured $3.5 million in funding from a prominent family office, strengthening its financial runway for the next 18 months. The investment marks a key step forward in advancing the company’s non-viral gene delivery platform toward clinical readiness. The funding represents a significant portion of DNA…
